Haleon (NYSE:HLN) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research cut shares of Haleon (NYSE:HLN) from a hold rating to a strong sell rating in a report released on Tuesday morning,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Rothschild & Co Redburn lowered Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Haleon presently has an average rating of “Moderate Buy”.

Haleon Price Performance

Shares of HLN opened at $9.86 on Tuesday. The company has a market cap of $43.41 billion, a P/E ratio of 25.27, a PEG ratio of 2.29 and a beta of 0.13. Haleon has a fifty-two week low of $8.65 and a fifty-two week high of $11.28. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. The firm’s 50 day moving average price is $9.33 and its 200 day moving average price is $9.85.

Institutional Trading of Haleon

Institutional investors have recently bought and sold shares of the business. Western Wealth Management LLC acquired a new position in shares of Haleon during the 1st quarter worth about $29,000. Parkside Financial Bank & Trust raised its position in shares of Haleon by 101.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after acquiring an additional 1,433 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC raised its position in shares of Haleon by 402.0% during the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after acquiring an additional 2,404 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Haleon by 428.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock worth $57,000 after purchasing an additional 5,124 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.